Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation.
BACKGROUND
Invasive mold infections (IMIs) are common in individuals who have undergone hematopoietic stem cell transplantation (HSCT). We sought to determine clinical and biological risk factors for different IMIs during each period (early and late) after allogeneic HSCT.


METHODS
Cases of proven and probable IMI diagnosed in HSCT recipients at the Fred Hutchinson Cancer Research Center (Seattle, WA) from 1 January 1998 through 31 December 2002 were included. Survival was estimated with Kaplan-Meier curves, and Cox regression models were used for multivariable analyses.


RESULTS
During the study period, 1248 patients underwent allogeneic HSCT; 163 (13.1%) received a diagnosis of probable or proven IMI. The majority of cases were caused by Aspergillus species (88%). The incidence of IMI caused by other molds remained low (<2%) over the 4-year study period. Risk factors for IMI early after HSCT and late after HSCT differed, with host variables (age) and transplant variables (human leukocyte antigen match) predominating as early risk factors and other clinical complications (graft-versus-host disease and cytomegalovirus disease) predominating later. Biological risk factors that were important during all periods included multiple cytopenias (neutropenia, lymphopenia, and monocytopenia) and iron overload.


CONCLUSIONS
Risk factors for invasive aspergillosis after allogeneic HSCT are multifactorial and differ according to timing after HSCT. Increased attention should be placed on understanding the immunopathogenesis of fungal disease after HSCT.
Garcia-Vidal
Carol
C
Fred Hutchinson Cancer Research Center, USA.
Upton
Arlo
A
Kirby
Katharine A
KA
Marr
Kieren A
KA
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D003586:Cytomegalovirus Infections / Q000150:complications; D005260:Female; D005658:Fungi / Q000145:classification / Q000302:isolation & purification*; D006086:Graft vs Host Disease / Q000150:complications; D006648:Histocompatibility; D006801:Humans; D015994:Incidence; D019190:Iron Overload; D053208:Kaplan-Meier Estimate; D007970:Leukopenia / Q000150:complications; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000453:epidemiology*; D016016:Proportional Hazards Models; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000009:adverse effects*; D014184:Transplantation, Homologous / Q000009:adverse effects*
Bone Marrow Transplant. 2006 May;37(9):857-64
16532017
J Immunol. 1995 Jan 1;154(1):268-80
7995946
Clin Infect Dis. 2004 May 1;38(9):1237-42
15127334
Herpes. 2003 May;10(1):12-6
12749798
Infect Immun. 2005 Nov;73(11):7170-9
16239511
Bone Marrow Transplant. 2004 Jul;34(2):115-21
15156166
J Infect Dis. 2003 Feb 15;187(4):705-9
12599092
J Infect Dis. 2005 Apr 15;191(8):1350-60
15776383
N Engl J Med. 2001 Jan 18;344(3):175-81
11172139
Clin Infect Dis. 2000 Jun;30(6):851-6
10852735
Bone Marrow Transplant. 1991;7 Suppl 2:6-8
1878723
Clin Infect Dis. 2002 Apr 1;34(7):909-17
11880955
Blood. 2006 Mar 15;107(6):2562-9
16322466
Bone Marrow Transplant. 1999 Aug;24(3):307-12
10455371
Int Arch Allergy Immunol. 2007;142(2):116-26
17057409
Biol Blood Marrow Transplant. 1999;5(2):55-68
10371357
Clin Infect Dis. 2002 Jan 1;34(1):7-14
11731939
J Infect Dis. 1995 Jun;171(6):1545-52
7769290
Infect Immun. 2003 Jun;71(6):3034-42
12761080
Gastroenterology. 1981 Mar;80(3):557-65
7450446
Blood. 1996 Nov 1;88(9):3634-41
8896434
Blood. 2002 Dec 15;100(13):4358-66
12393425
Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):47-9
16399584
Lancet Infect Dis. 2003 Mar;3(3):156-61
12614732
Curr Opin Infect Dis. 2003 Dec;16(6):607-12
14624113
Blood. 2003 Aug 1;102(3):827-33
12689933
Blood. 1994 Sep 15;84(6):2036-43
8081005
Bone Marrow Transplant. 2002 Jan;29(1):15-9
11840139
Chest. 2005 Jan;127(1):295-307
15653997
Bone Marrow Transplant. 2005 Oct;36(7):621-9
16044133
PLoS Genet. 2008 Jun 20;4(6):e1000101
18566672